# Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

> **NCT04686994** · PHASE1 · COMPLETED · sponsor: **Gannex Pharma Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Overweight and Obesity
- NAFLD
- Hyperlipidemia

## Interventions

- **DRUG:** ASC 41
- **DRUG:** ASC 41 Placebo

## Key facts

- **NCT ID:** NCT04686994
- **Lead sponsor:** Gannex Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2021-01-19
- **Final completion:** 2021-02-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04686994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04686994, "Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04686994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*